Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.34 |
| ▸ | TMIGD3 | P0DMS9 | 4/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.33 |
| ▸ | NT5E | P21589 | 5/20 | 0.31 |
| ▸ | SERPINA3 | P01011 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13777764 | 0.89 | PDE3A (0.34) | — | |
| SCHEMBL13777718 | 0.81 | ADORA2A (0.36) | ADORA2AADORA1ADORA3 | |
| SCHEMBL13625892 | 0.80 | GRIN2B (0.40) | ADORA1 | |
| SCHEMBL13625768 | 0.79 | ADORA3 (0.32) | ADORA3 | |
| SCHEMBL13625863 | 0.78 | ADORA3 (0.36) | ADORA2AADORA3 | |
| SCHEMBL13626076 | 0.77 | ADORA3 (0.34) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL13625683 | 0.77 | ADORA3 (0.34) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL13777716 | 0.77 | ADORA3 (0.32) | ADORA2AADORA1ADORA3 | |
| SCHEMBL13819681 | 0.77 | ACACB (0.32) | — | |
| SCHEMBL13819686 | 0.76 | MEN1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170803-A1 | ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170803-A1 | ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES | ADORA2A, PDE4A, PDE4B | ADORA2A 1/4885ADORA1 10/4885TMIGD3 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.